Support & Resources

See below to find helpful information for your practice and important resources to support your patients who are prescribed OGSIVEO.

Resources for Healthcare Professionals

OGSIVEO Launch Broadcasts

Watch desmoid tumor experts present on OGSIVEO and desmoid tumors.

ICD-10-CM Codes for Desmoid Tumors

Location-specific ICD-10-CM codes for desmoid tumors went into effect on October 1, 2023. The codes can help you document specific desmoid tumor diagnoses in your patients.

Resources to Support OGSIVEO Patients

Patient Brochure

This brochure provides an overview of OGSIVEO for patients considering or starting treatment.

It includes safety information, dosing instructions, educational content on desmoid tumors, and more.

Sarcoma Centers

You can find a list of sarcoma centers on the website for Sarcoma Alliance for Research through Collaboration (SARC), a non-profit organization.*

SARC is independent of SpringWorks Therapeutics. SpringWorks Therapeutics is providing this resource to help patients find healthcare professionals by location who have experience treating adults with desmoid tumors. Inclusion of a healthcare setting in this locator directory does not represent an endorsement, referral, or recommendation from SpringWorks Therapeutics and is not intended as medical advice. The healthcare professionals or institutions included in this locator directory do not necessarily prescribe or endorse any SpringWorks Therapeutics products. This locator directory is not comprehensive and other providers with experience treating adults with desmoid tumors may be available.

SpringWorks CareConnection logo

Connections at Each Point of Care

SpringWorks CareConnectionsTM provides personalized support services and resources to help your patients start and stay on track with OGSIVEO

Coverage and Access Support

  • Resources and assistance to support timely access to OGSIVEO
  • Quick Start Program–CareConnections can help eligible commercially insured patients who are experiencing a qualified delay in their insurance coverage get started on OGSIVEO at no cost for a limited period of time
  • Bridge Program–Eligible commercially insured patients currently on OGSIVEO experiencing a qualified lapse in their insurance coverage may be able to receive OGSIVEO at no cost for a limited period of time

Financial Assistance

  • Connect your patients to financial assistance options that may be available
  • Commercial Copay Program–Eligible patients with commercial insurance may pay as little as a $0 copay for OGSIVEO
    • To find out if your patient is eligible for the Commercial Copay Program, contact SpringWorks CareConnections at 844-CARES-55 (844-227-3755), Monday – Friday 8 AM – 10 PM ET, to speak with a Nurse Advocate
  • Patient Assistance Program–Patients who are uninsured, underinsured, or lack coverage for OGSIVEO may be eligible to receive medication at no cost§

Personalized Educational and Emotional Support

  • Dedicated Nurse Advocates provide personalized support and serve as a single point of contact for your patients regardless of where they are in their treatment journey

Field Access Manager
(FAM) Capabilities

  • FAMs can provide in person or virtual support to help facilitate access to OGSIVEO by providing you and your office staff regional payer education and timely responses to questions

For further information or questions about enrolling your patients, contact SpringWorks CareConnections today

Terms and conditions apply. Full terms and conditions provided during enrollment process and are available upon request by contacting SpringWorks CareConnections at 844-CARES-55 (844-227-3755).

Terms and conditions apply. Copay program is subject to an annual benefit maximum. Full terms and conditions provided during enrollment process and are available upon request by contacting SpringWorks CareConnections at 844-CARES-55 (844-227-3755).

Terms and conditions apply. PAP eligibility criteria and annual household income limits apply. Full terms and conditions provided during enrollment process and are available upon request by contacting SpringWorks CareConnections at 844-CARES-55 (844-227-3755).

PAP, patient assistance program.

How to Order and Prescribe

OGSIVEO is available through a limited Specialty Pharmacy network.

OGSIVEO is also available for eligible medically integrated dispensing pharmacies by ordering directly through one of our Specialty Distributor partners.

Prescribe OGSIVEO using one of the following options:

  1. SpringWorks CareConnections – Complete the enrollment form, including Section 8 Prescription for OGSIVEO, choose a fulfillment option from our in-network Specialty Pharmacy partners, and OGSIVEO will be shipped directly to the patient
  2. Prescribe directly through a Specialty Pharmacy network or medically integrated dispensing (MID) pharmacy – Eligible MID pharmacy practices may purchase OGSIVEO direct through our Specialty Distributors

May not be available for all practices or organizations.

Specialty Pharmacies
Biologics by McKesson
Phone: 800-850-4306
Fax: 800-823-4506
Phone: 877-662-6633
Fax: 877-662-6355
Specialty Distributors
ASD Healthcare (Hospitals)
Phone: 800-746-6273
Fax: 800-547-9413
Oncology Supply (Clinics)
Phone: 800-633-7555
Fax: 800-248-8205
Cardinal Health
Cardinal Health SPD (Acute)
Phone: 855-855-0708
Fax: 614-553-6301
Cardinal Health SPD (Provider)
Phone: 877-453-3972
Fax: 877-274-9897
McKesson Specialty Health
Phone: 800-482-6700
Fax: 855-824-9489
McKesson Plasma and Biologics
Phone: 877-625-2566
Fax: 888-752-7626

Advocacy Groups

The following advocacy organizations can provide additional support and information for your patients with desmoid tumors.

The organizations listed are independent of SpringWorks Therapeutics. SpringWorks Therapeutics is providing these links to help patients find more information about desmoid tumors, but inclusion on this list does not represent an endorsement or a recommendation from SpringWorks Therapeutics for any group or organization. Logos are used with permission.

Important Safety Information


OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.

Important Safety Information

Warnings and Precautions

Diarrhea: Diarrhea, sometimes severe, can occur in patients treated with OGSIVEO. Diarrhea occurred in 84% of patients treated with OGSIVEO, and included Grade 3 events in 16% of patients. Median time to first diarrhea event was 9 days (range: 2 to 434 days). Monitor patients and manage using antidiarrheal medications. Modify dose as recommended.

Ovarian Toxicity: Female reproductive function and fertility may be impaired in patients treated with OGSIVEO. Impact on fertility may depend on factors like duration of therapy and state of gonadal function at time of treatment. Long-term effects of OGSIVEO on fertility have not been established. Advise patients on the potential risks for ovarian toxicity before initiating treatment. Monitor patients for changes in menstrual cycle regularity or the development of symptoms of estrogen deficiency, including hot flashes, night sweats, and vaginal dryness.

Hepatotoxicity: ALT or AST elevations occurred in 30% and 33% of patients, respectively. Grade 3 ALT or AST elevations (>5 x ULN) occurred in 6% and 2.9% of patients. Monitor liver function tests regularly and modify dose as recommended.

Non-Melanoma Skin Cancers: New cutaneous squamous cell carcinoma and basal cell carcinoma occurred in 2.9% and 1.4% of patients, respectively. Perform dermatologic evaluations prior to initiation of OGSIVEO and routinely during treatment.

Electrolyte Abnormalities: Decreased phosphate (65%) and potassium (22%) occurred in OGSIVEO-treated patients. Phosphate <2 mg/dL occurred in 20% of patients. Grade 3 decreased potassium occurred in 1.4% of patients. Monitor phosphate and potassium levels regularly and supplement as necessary. Modify dose as recommended.

Embryo-Fetal Toxicity: OGSIVEO can cause fetal harm when administered to pregnant women. Oral administration of nirogacestat to pregnant rats during the period of organogenesis resulted in embryo-fetal toxicity and death at maternal exposures below human exposure at the recommended dose of 150 mg twice daily. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during treatment with OGSIVEO and for 1 week after the last dose.

Adverse Reactions

The most common (≥15%) adverse reactions were diarrhea (84%), ovarian toxicity (75% in the 36 females of reproductive potential), rash (68%), nausea (54%), fatigue (54%), stomatitis (39%), headache (30%), abdominal pain (22%), cough (20%), alopecia (19%), upper respiratory tract infection (17%), and dyspnea (16%).

Serious adverse reactions occurred in 20% of patients who received OGSIVEO. Serious adverse reactions occurring in ≥2% of patients were ovarian toxicity (4%).

The most common laboratory abnormalities (≥15%) were decreased phosphate, increased urine glucose, increased urine protein, increased AST, increased ALT, and decreased potassium.

Drug Interactions

CYP3A Inhibitors and Inducers: Avoid concomitant use with strong or moderate CYP3A inhibitors (including grapefruit products, Seville oranges, and starfruit) and strong or moderate CYP3A inducers.

Gastric Acid Reducing Agents: Avoid concomitant use with proton pump inhibitors and H2 blockers. If concomitant use cannot be avoided, OGSIVEO can be staggered with antacids (e.g., administer OGSIVEO 2 hours before or 2 hours after antacid use).

Consult the full Prescribing Information prior to and during treatment for important drug interactions.

Use in Specific Populations

Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with OGSIVEO and for 1 week after the last dose.

Please click here for full Prescribing Information.

Important Safety Information

DeFi, Desmoid Fibromatosis; HCP, healthcare professional; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NCCN, National Comprehensive Cancer Network® (NCCN®); PAP, patient assistance program.